Measured
in output.

PubMed Indexed
Articles

93 verified PubMed-indexed articles (compiled August 2026), listed reverse-chronologically in Vancouver style.

1. 1Sharma A, Abdelshafy Tabl A, Rihani HT, Tabl MA, Shebl AA, Abousaif WS, et al. Real-world effectiveness and safety of ranibizumab biosimilar FYB-201 in Saudi Arabia (Ravegza) and Jordan (Uptera): a middle eastern extension of the FORCE study. Eye (Lond). 2026;40(10):1427-1430. DOI
2. 2Sharma A, Khanani AM, Eichenbaum D, Boyer D, Shaer A, Ortiz T, et al. Aflibercept 2 mg Biosimilar (aflibercept-ayyh, Pavblu): Experience of safety in clinical settings-APEX-safety study. Eye (Lond). 2026;40(6):751-754. DOI
3. 3Song JR, Park UC, Lee CS, Cho JJ, Kim JY, Baek SC, et al. Real-world outcomes of ranibizumab biosimilars in various retinal diseases: a Korean multi-center experience-ROSE Korea Study. Sci Rep. 2026;16(1):4220. DOI
4. 4Sharma A, Nicholson L, Vazquez-Alfageme C, Sivagnanavel V, Fausto R, Soare MC, et al. FYB-201 Biosimilar ranibizumab (Ongavia/Ranivisio/Cimerli) Efficacy and Safety in Clinical Settings-FORCE study. Eye (Lond). 2025;39(17):3129-3134. DOI
5. 5Avadzadeh S, Sharma A, Parvaresh MM, Ghasemi Falavarjani K, Kumar N. Aflibercept 2 mg biosimilar (Tyalia)-real-world experience from IRAN (ATRIA study). Eye (Lond). 2025;39(11):2159-2163. DOI
6. 6Sharma A, Bandello F, Bandyopadhyay S, Kumar N, Parachuri N. Aflibercept vs ranibizumab biosimilars: manufacturing differences that might matter in the long run. Eye (Lond). 2025;40(2):168-169. DOI
7. 7Sharma A, Regillo CD, Nicholson L, Kumar N, Parachuri N, Wakabayashi T, et al. The conundrum of abundance: challenges of having too many biosimilars. Expert Opin Biol Ther. 2025;25(6):573-576. DOI
8. 8Sharma A, Holz FG, Kumar N, Sarraf D, Ayachit S, Mishra C, et al. Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study. J Vitreoretin Dis. 2025;9(3):330-335. DOI
9. 9Sharma A, Woo SJ, Lee CS, Kumar N, Parachuri N, Bandello F, et al. Aflibercept 2 mg biosimilars-will they lead the Anti-VEGF biosimilar world globally. Eye (Lond). 2025;39(6):1026-1027. DOI
10. 10Sharma A, Kaiser PK, Tadayoni R, Holz FG, Nicholson L, Vazquez-Alfageme C, et al. Anti-VEGF Biosimilars for Retinal Diseases Survey 2023-India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI). Eye (Lond). 2024;38(17):3392-3395. DOI
11. 11Sharma A, Wakabayashi T, Regillo CD, Cheung CMG, Loewenstein A, Zur D, et al. Subfoveal neurosensory detachment flattening and observe (SNF-Ob) approach for the management of Ci-DMO - a multicentric study. Eye (Lond). 2024;38(17):3272-3278. DOI
12. 12Ueda-Consolvo T, Ishida M, Nakamura T, Yanagisawa S, Tsuboi K, Wakabayashi T, et al. Biosimilar ranibizumab (BS1)-early experience from Japan (BRIJ study). Eye (Lond). 2024;38(16):3193-3196. DOI
13. 13Sharma A, Kumar N, Parachuri N, Loewenstein A, Bandello F, Kuppermann BD. Global experience of faricimab in clinical settings - a review. Expert Opin Biol Ther. 2024;24(4):263-268. DOI
14. 14Sharma A, Kumar N, Parachuri N, Bandello F, Loewenstein A, Kuppermann BD. Biosimilar ranibizumab in India-overview of phase 3 clinical trial designs. Eye (Lond). 2024;38(10):1796-1798. DOI
15. 15Agrawal D, Heda A, Ghosh S, Kalia S, Bhatia K, Kumar N, Tripathy K. Knowledge, attitude, and practice patterns of Indian ophthalmologists regarding medicolegal issues. Indian J Ophthalmol. 2023;71(12):3690-3695. DOI
16. 16Sharma A, Loewenstein A, Parachuri N, Kumar N, Kuppermann BD. Biosimilar to Biosimilar Anti-VEGF Switching for Retinal Diseases. J Vitreoretin Dis. 2023;7(6):474-476. DOI
17. 17Sharma A, Loewenstein A, Kumar N, Parachuri N, Bandello F, Kuppermann BD. Aflibercept biosimilars-update on the development progress. Eye (Lond). 2023;38(5):824-825. DOI
18. 18Sharma A, Loewenstein A, Parachuri N, Kumar N, Rasal A, Bandello F, Kuppermann BD. Biosimilar anti-VEGF-is prefilled syringe (PFS) a challenge? Eye (Lond). 2023;38(2):244-245. DOI
19. 19Sharma A, Kumar N, Parachuri N, Bandello F. Re: Zhang et al.: The biosimilar paradox: how anti-VEGF biosimilars will increase patient and overall healthcare costs (Ophthalmology. 2023;130:966-973). Ophthalmology. 2023;130(11):e40-e41. DOI
20. 20Sharma A, Kumar N, Parachuri N, Loewenstein A, Bandello F, Kuppermann BD. Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South Asia. Expert Opin Biol Ther. 2023;23(8):689-692. DOI
21. 21Sharma A, Holz FG, Regillo CD, Freund KB, Sarraf D, Khanani AM, et al. Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER survey). Expert Opin Biol Ther. 2023;23(8):851-859. DOI
22. 22Sharma A, Khanani AM, Parachuri N, Kumar N, Bandello F, Kuppermann BD. Port delivery system with ranibizumab (Susvimo) recall-what does it mean to the retina specialists. Int J Retina Vitreous. 2023;9(1):6. DOI
23. 23Kumar N, Sharma A. Commentary: The tinsels and tassels of smartphone ophthalmic photography. Indian J Ophthalmol. 2023;71(1):295-296. DOI
24. 24Sharma A, Kumar N, Kuppermann BD. Biosimilar Ranibizumab and Innovator Ranibizumab-Immunogenicity Assessment and Its Impact on Safety and Efficacy. JAMA Ophthalmol. 2023;141(2):128-129. DOI
25. 25Sharma A, Kumar N, Parachuri N, Bandello F, Kuppermann BD. Immunogenicity: Clouding the Future of Intravitreal Therapy. Ocul Immunol Inflamm. 2022;31(9):1746-1749. DOI
26. 26Sharma A, Kumar N, Parachuri N, Regillo C, Bandello F, Kuppermann BD. Biosimilar ranibizumab interchangeability: what does it mean to retinal physicians? Eye (Lond). 2022;37(10):1953-1954. DOI
27. 27Sharma A, Kondo M, Iwahashi C, Parachuri N, Kumar N, Bandello F, et al. Approved biosimilar ranibizumab-a global update. Eye (Lond). 2022;37(2):200-202. DOI
28. 28Sharma A, Parachuri N, Kumar N, Bandello F, Kuppermann BD. Biosimilar anti-VEGF-yardsticks to ensure biosimilarity. Eye (Lond). 2022;37(1):4-5. DOI
29. 29Sharma A, Parachuri N, Kumar N, Kuppermann BD, Loewenstein A, Bandello F. Brolucizumab in polypoidal choroidal vasculopathy. Expert Opin Biol Ther. 2022;22(7):809-812. DOI
30. 30Sharma A, Kumar N, Parachuri N, Kuppermann BD, Bandello F. Supplemental nutrition for retinal health: Evidence based analysis of commercial preparations in India. Indian J Ophthalmol. 2022;70(6):2061-2064. DOI
31. 31Sharma A, Parachuri N, Kumar N, Bandello F, Kuppermann BD. Fear of safety compromise with biosimilar anti-VEGF-perception or truth. Eye (Lond). 2022;36(11):2086-2087. DOI
32. 32Sharma A, Parachuri N, Kumar N, Kuppermann BD, Bandello F, Regillo CD. The port delivery system with ranibizumab: understanding nuances for clinical use in the real world. Expert Opin Biol Ther. 2022;22(6):675-677. DOI
33. 33Sharma A, Arunaprakash J, Das A, Nayaka A, Kumar N, Parachuri N, Kuppermann BD. Ranizurel safety evaluation in real-world-(RaSER) study. Am J Ophthalmol Case Rep. 2022;25:101358. DOI
34. 34Sharma A, Kumar N, Parachuri N, Regillo CD, Bandello F, Kuppermann BD. Retina: a unique subspecialty in the biosimilar landscape. Eye (Lond). 2022;36(6):1145-1146. DOI
35. 35Sharma A, Kumar N, Parachuri N, Loewenstein A, Bandello F, Kuppermann BD. On label bevacizumab for retina: where it stands. Eye (Lond). 2022;36(5):916-917. DOI
36. 36Sharma A, Kumar N, Parachuri N, Sahyoun JY, Kuppermann BD, Bandello F. Brolucizumab-termination of 4 weekly trials-rebalancing the immunogenicity risk. Expert Opin Biol Ther. 2022;22(4):441-443. DOI
37. 37Sharma A, Parachuri N, Kumar N, Romano MR, Parolini B, Ozdek S, et al. Myths and truths of the association of retinal vascular occlusion with COVID-19. Retina. 2022;42(3):413-416. DOI
38. 38Sharma A, Gemmy Cheung CM, Arias-Barquet L, Ozdek S, Parachuri N, Kumar N, et al. Reply. Retina. 2022;42(3):e20-e22. DOI
39. 39Sharma A, Kumar N, Parachuri N, Karanam D, Kuppermann BD, Bandello F, Regillo CD. Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials. Eye (Lond). 2021;36(4):679-680. DOI
40. 40Sharma A, Parachuri N, Kumar N, Kuppermann BD, Bandello F. The Port Delivery System with ranibizumab-journey of mitigating vitreous hemorrhage. Eye (Lond). 2021;36(3):488-489. DOI
41. 41Kumar N, Sharma A, Tripathy K. Commentary: Big data in Ophthalmology: A big game changer on horizon. Indian J Ophthalmol. 2021;69(11):3188-3189. DOI
42. 42Chakraborty D, Mondal S, Parachuri N, Kumar N, Sharma A. Brolucizumab-early experience with early extended interval regime in chronic centre involved diabetic macular oedema. Eye (Lond). 2021;36(2):358-360. DOI
43. 43Kumar N, Parachuri N, Sharma A. Commentary: Acute central serous chorioretinopathy-Treat early, observe longer. Indian J Ophthalmol. 2021;69(9):2347-2348. DOI
44. 44Sharma A, Parachuri N, Kumar N, Saboo B, Tripathi HN, Kuppermann BD, Bandello F. Semaglutide and the risk of diabetic retinopathy-current perspective. Eye (Lond). 2021;36(1):10-11. DOI
45. 45Sharma A, Cheung CMG, Arias-Barquet L, Ozdek S, Parachuri N, Kumar N, et al. Fluid-based visual prognostication in type 3 macular neovascularization-FLIP-3 study. Retina. 2022;42(1):107-113. DOI
46. 46Sharma A, Kumar N, Parachuri N, Bandello F, Kuppermann BD, Loewenstein A. Faricimab: Two in the Bush Is Proving Better than One in the Hand? Ocul Immunol Inflamm. 2021;30(7-8):1961-1963. DOI
47. 47Sharma A, Kumar N, Parachuri N, Bandello F, Kuppermann BD, Loewenstein A. Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)-efficacy and safety (BIRA study). Eye (Lond). 2021;36(5):1106-1107. DOI
48. 48Sharma A, Kumar N, Parachuri N, Singh S, Bandello F, Regillo CD, Boyer D, Nguyen QD. Understanding Retinal Vasculitis Associated with Brolucizumab: Complex Pathophysiology or Occam's Razor? Ocul Immunol Inflamm. 2021;30(6):1508-1510. DOI
49. 49Sharma A, Kumar N, Parachuri N. Biosimilar Ranibizumab (SB11) vs Reference Ranibizumab-Diving Deeper for Safety and Efficacy. JAMA Ophthalmol. 2021;139(6):677-679. DOI
50. 50Sharma A, Parachuri N, Kumar N, Bandello F, Kuppermann BD, Loewenstein A, et al. Terms non-exudative and non-neovascular: awaiting entry at the doors of AMD reclassification. Graefes Arch Clin Exp Ophthalmol. 2021;259(6):1381-1383. DOI
51. 51Sharma A, Kumar N, Parachuri N. Re: Kunimoto et al.: Efficacy and safety of abicipar in neovascular age-related macular degeneration: 52-week results of phase 3 randomized controlled study (Ophthalmology. 2020:127:1331-1334). Ophthalmology. 2021;128(6):e30. DOI
52. 52Sharma A, Kumar N, Parachuri N, Bandello F, Kuppermann BD, Loewenstein A, et al. Understanding the Mechanisms of Fluid Development in Age-Related Macular Degeneration. Ophthalmol Retina. 2021;5(2):105-107. DOI
53. 53Sharma A, Kumar N, Parachuri N, Kuppermann BD, Bandello F, Regillo CD, Boyer D, Nguyen QD. Brolucizumab-foreseeable workflow in the current scenario. Eye (Lond). 2021;35(6):1548-1550. DOI
54. 54Sharma A, Parachuri N, Kumar N, Bandello F, Kuppermann BD, Loewenstein A, Regillo CD, Chakravarthy U. Vortex vein anastomosis and pachychoroid-an evolving understanding. Eye (Lond). 2021;35(6):1545-1547. DOI
55. 55Sharma A, Kumar N, Parachuri N, Sadda SR, Corradetti G, Heier J, et al. Correction: Brolucizumab-early real-world experience: BREW study. Eye (Lond). 2021;35(4):1286. DOI
56. 56Sharma A, Kumar N, Parachuri N, Bandello F, Kuppermann BD, Loewenstein A. Biosimilars for Retinal Diseases: An Update. Am J Ophthalmol. 2020;224:36-42. DOI
57. 57Sharma A, Parachuri N, Kumar N, Bandello F, Kuppermann BD, Loewenstein A, Regillo C, Chakravarthy U. Fluid-based prognostication in n-AMD: Type 3 macular neovascularisation needs an analysis in isolation. Br J Ophthalmol. 2020;105(3):297-298. DOI
58. 58Sharma A, Kumar N, Parachuri N, Singh S, Bandello F, Kuppermann BD, Loewenstein A. Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world. Eye (Lond). 2020;35(5):1292-1294. DOI
59. 59Sharma A, Parachuri N, Kumar N, Bandello F, Kuppermann BD, Loewenstein A, et al. Notion of tolerating subretinal fluid in neovascular AMD: understanding the fine print before the injection pause. Br J Ophthalmol. 2020;105(2):149-150. DOI
60. 60Sharma A, Kumar N, Bandello F, Kuppermann BD, Loewenstein A, Regillo CD. Brolucizumab: the road ahead. Br J Ophthalmol. 2020;104(12):1631-1632. DOI
61. 61Kaur R, Singh H, Samria S, Kumar N, Parachuri N, Sharma R, et al. Correction: MII RetCam assisted smartphone-based fundus imaging (MSFI)-a boon for paediatric retinal imaging. Eye (Lond). 2021;35(3):1029. DOI
62. 62Kumar N, Bandello F, Kuppermann BD, Sharma A. Correction: Comment on: 'Recent advances in anterior chamber angle imaging'. Eye (Lond). 2020;34(10):1943. DOI
63. 63Sharma A, Kumar N, Parachuri N, Sadda SR, Corradetti G, Heier J, et al. Brolucizumab-early real-world experience: BREW study. Eye (Lond). 2020;35(4):1045-1047. DOI
64. 64Sharma A, Bandello F, Loewenstein A, Kuppermann BD, Lanzetta P, Zur D, et al. Current role of intravitreal injections in Irvine Gass syndrome-CRIIG study. Int Ophthalmol. 2020;40(11):3067-3075. DOI
65. 65Sharma A, Kumar N, Singh S, Regillo CD, Freund KB. Management of Fluid in Neovascular Age-related Macular Degeneration: To Mop it, to Dab it, or to Leave it? Retina. 2020;40(8):1451-1455. DOI
66. 66Patil J, Patil L, Parachuri N, Kumar N, Bandello F, Kuppermann BD, Loewenstein A, Sharma A. Smartphone based ROP (S-ROP) screening-opportunities and challenges. Eye (Lond). 2020;34(9):1512-1514. DOI
67. 67Sheth J, Anantharaman G, Kumar N, Parachuri N, Bandello F, Kuppermann BD, et al. Pachydrusen: the epidemiology of pachydrusen and its relevance to progression of pachychoroid disease spectrum. Eye (Lond). 2020;34(9):1501-1503. DOI
68. 68Sharma A, Parachuri N, Kumar N, Sharma R, Bandello F, Kuppermann BD, Loewenstein A. Brolucizumab-another anti-VEGF or beyond. Eye (Lond). 2020;34(9):1499-1500. DOI
69. 69Sharma A, Kumar N, Parachuri N, Sharma R, Bandello F, Kuppermann BD, Loewenstein A. Brolucizumab and immunogenicity. Eye (Lond). 2020;34(10):1726-1728. DOI
70. 70Sharma A, Parachuri N, Kumar N, Sharma R, Bandello F, Kuppermann BD, Loewenstein A. Brolucizumab-key learnings from HAWK and HARRIER. Eye (Lond). 2020;34(8):1318-1320. DOI
71. 71Sharma A, Kumar N, Parachuri N, Sharma R, Bandello F, Kuppermann BD, Regillo CD. Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD). Eye (Lond). 2020;34(8):1310-1312. DOI
72. 72Kaur R, Singh H, Samria S, Kumar N, Parachuri N, Sharma R, et al. MII RetCam assisted smartphone-based fundus imaging (MSFI)-A boon for paediatric retinal imaging. Eye (Lond). 2020;34(8):1307-1309. DOI
73. 73Kumar N, Bandello F, Kuppermann BD, Sharma A. Comment on: 'Recent advances in anterior chamber angle imaging'. Eye (Lond). 2020;34(10):1939. DOI
74. 74Bilong Y, Domngang CN, Nwanlih Gimma G, Katte JC, Afetane TE, Kagmeni G, et al. Smartphone-Assisted Glaucoma Screening in Patients With Type 2 Diabetes: a Pilot Study. Med Hypothesis Discov Innov Ophthalmol. 2020;9(1):61-65..
75. 75Sharma A, Hafeez Faridi M, Kumar N, Parachuri N, Sharma R, Kuppermann BD, et al. Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data. Eye (Lond). 2019;34(6):1008-1009. DOI
76. 76Sharma A, Kumar N, Bandello F, Loewenstein A, Kuppermann BD. Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect. Eye (Lond). 2019;34(6):1006-1007. DOI
77. 77Sharma A, Kumar N, Bandello F. Re: Dugel et al: HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2019;126(12):e95-e96. DOI
78. 78Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Faricimab: expanding horizon beyond VEGF. Eye (Lond). 2019;34(5):802-804. DOI
79. 79Sharma A, Kumar N, Kuppermann BD, Bandello F. Re: Campochiaro et al.: The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial. Ophthalmology. 2019;126(11):e87-e88. DOI
80. 80Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Ophthalmic biosimilars and biologics-role of endotoxins. Eye (Lond). 2019;34(4):614-615. DOI
81. 81Sharma A, Kumar N, Kuppermann BD, Bandello F. Abicipar pegol: the non-monoclonal antibody anti-VEGF. Eye (Lond). 2019;34(5):797-801. DOI
82. 82Sharma A, Kumar N, Kuppermann BD, Bandello F. Brolucizimab-leading an era of structural revolution for long-term VEGF suppression. Eye (Lond). 2019;34(4):611-613. DOI
83. 83Sharma A, Kumar N, Kuppermann BD, Loewenstein A, Bandello F. Brolucizumab: is extended VEGF suppression on the horizon? Eye (Lond). 2019;34(3):424-426. DOI
84. 84Sharma A, Parachuri N, Kumar N, Kuppermann BD, Bandello F, Loewenstein A, Regillo CD. Subfoveal Neurosensory Detachment Flattening and Observe (SNF-Ob): A Novel Approach in Diabetic Macular Edema Management. Ophthalmol Retina. 2019;3(11):1009-1011. DOI
85. 85Sharma A, Goyal A, Bilong Y, Shah P, Banker A, Kumar N, et al. Comparison of a Smartphone-Based Photography Method with Indirect Ophthalmoscopic Assessment in Referable Retinopathy of Prematurity. Ophthalmol Retina. 2019;3(10):911-912. DOI
86. 86Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Ophthalmic biosimilars: Lessons from India. Indian J Ophthalmol. 2019;67(8):1384-1385. DOI
87. 87Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective. Br J Ophthalmol. 2019;104(1):2-7. DOI
88. 88Sharma A, Kumar N, Bandello F, Loewenstein A, Freund KB. Understanding Intravitreal Silicone Oil Droplets Due to Intravitreal Injections. Retina. 2019;39(7):1233-1235. DOI
89. 89Kumar N, Bandello F, Sharma A. Smartphone-based Gonio-Imaging: A Novel Addition to Glaucoma Screening Tools. J Glaucoma. 2019;28(9):e149-e150. DOI
90. 90Sharma A, Kumar N, Parachuri N, Kuppermann BD, Bandello F, Regillo CD. Ranibizumab port delivery system (RPDS): realising long awaited dream of prolonged VEGF suppression. Eye (Lond). 2019;34(3):422-423. DOI
91. 91Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Biotherapeutics and immunogenicity: ophthalmic perspective. Eye (Lond). 2019;33(9):1359-1361. DOI
92. 92Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Biologics, biosimilars, and biobetters: different terms or different drugs? Eye (Lond). 2019;33(7):1032-1034. DOI
93. 93Kumar Nilay, Garg N, Kumar N, Van Wagoner N. Bacillus cereus panophthalmitis associated with injection drug use. Int J Infect Dis. 2014;26:165-166. DOI

Selected awards & recognitions

From CV archives (through 2023–24) and continuing recognition at national forums.

• 1st Prize — When going gets tough, the tough gets going @ AIOC 2024
• Best Paper of the Session — Glaucoma-II, AIOC 2023
• Best Free Paper — Glaucoma Session, AIOC-MTC Vizag
• 2nd Prize — Innovators’ Forum 2021 by AIOS
• Winner — Yen-novation 2020, Yenepoya University
• Winner — All India Talent Search Program, AIOS SC 2020
• Winner — Think Under the Apple Tree (Innovation), AIOC 2020
• 2nd Prize — Innovations, TNOA Salem EyeCon 2019
• 2nd Prize — Essay Writing Competition by YOSI-AIOS at AIOC 2019
• Travel grant — AIOC 2020